Aspirin halves the risk of recurrence in patients with colorectal cancer, clinical trial finds

A Swedish-led research team at Karolinska Institutet and Karolinska University Hospital has shown in a new randomized clinical trial that a low dose of the well-known medicine aspirin halves the risk of recurrence after surgery in patients with colon and rectal cancer with a certain type of genetic alteration in the tumor.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup